93 results about "Oral hypoglycemic" patented technology

The combination of a HMG CoA reductase inhibitor like a statin, such as simvastatin, with a pFox inhibitor such as trimetazidine (“Simetazidine”) is particularly advantageous for treatment of end-stage complications, such as acute coronary syndrome (ACS) and chronic angina, especially in type II diabetics. The combination therapy is also useful in the treatment and/or prevention of chronic heart failure (CHF) and peripheral arterial disease (PAD). The combination of a nitric oxide (NO) mechanism with increased NO production with pFox inhibition simultaneously treats both the effect and the cause of angina. One or more oral hypoglycemic compounds (biguanides, insulin sensitizers, such as thiazolidinediones, α-glucosidase inhibitors, insulin secretagogues, and dipeptidyl peptidase IV inhibitors), protein kinase C (PKC) inhibitors, and acetyl-CoA carboxylase inhibitors can also be used in combination with the HMG CoA reductase inhibitors and/or pFox inhibitors, especially in type II diabetics, to control glucose levels and treat endothelial dysfunction. The drugs can be given in combination (e.g. a single tablet) or in separate dosage forms, administered simultaneously or sequentially. In the preferred form the statin is given in a dose of between 5 and 80 mg/day in two separate doses, and the pFox inhibitor is administered in a sustained or extended dosage formulation at a dose of 20 mg three times a day or 35 mg two times a day. The dose of the oral hypoglycemic, PKC inhibitor, or acetyl-CoA carboxylase inhibitor varies with the type of drug used.

Compositions and methods for treating type 2 diabetes and its sequelae by intravenous or subcutaneous administration of formulations of synthesized curcumin (diferuloylmethane) and concomitantly one or more anti-diabetic agents to human subjects are disclosed herein. The composition of the present invention may be used to: (i) treat patients with diabetes in advanced stages with evidence of any or all encephalopathy, retinopathy, nephropathy, pancreatitis or neoplasias; (ii) treat patients with diabetic disease status without symptomatic or pathologic evidence of associated sequelae but requiring better glycemic control than that offered by standard of care anti-diabetic; and (iii) patients with objective signs or symptoms of sequelae from diabetes of anti-diabetic drugs. One three-drug combination of the present invention includes a slow release PLGA-curcumin and an oral gliptin (DPP-4)-inhibitor or any incretin-mimetic and metformin.

The invention relates to the technical field of medicaments. Dimethyldiguanide belongs to a biguanides oral hypoglycemic medicament and is widely applied to pharmaceutical therapy of type 2 diabetes. The invention aims at providing a novel application of the dimethyldiguanide and particularly an application of the dimethyldiguanide in preparation of medicaments for preventing or treating the hepatocellular carcinoma. According to the application disclosed by the invention, the restriction effect of the dimethyldiguanide on the hepatocellular carcinoma is found by research from two aspects, namely, cell culture in vitro and animal experiment in vivo. Experiments find that the dimethyldiguanide has the capabilities of restricting proliferation and clone formation of a hepatocellular carcinoma cell line and causing the cell cycle arrest and apoptosis increase of the hepatocellular carcinoma cell line, and also has the capability of enhancing the hepatocellular carcinoma resisting effect of chemotherapeutics when combined with the chemotherapeutics, such as cis-platinum, doxorubicin and the like. The invention provides the novel application of the dimethyldiguanide and also provides a novel concept for prevention and treatment of the hepatocellular carcinoma.

The invention discloses lithocarpus litseifolius total flavone extracted by using plant lithocarpus litseifolius as a raw material to develop a new hypoglycemic medicament, and provides a method for preparing the lithocarpus litseifolius total flavone. The purity of the lithocarpus litseifolius total flavone prepared by the method can reach over 80 percent, the phloridzin content reaches over 65 percent, the process is simple and has low energy consumption, and the technological condition is reasonable, stable and feasible. A hypoglycemic capsule developed by using the lithocarpus litseifolius total flavone can provide a convenient, acceptant and long-term taking oral hypoglycemic preparation for diabetics.

Methods and compositions for improving the delivery and/or efficacy of a therapy (e.g., an anti-cancer, anti-fibrotic or anti-inflammatory therapy) are disclosed. The invention is based, at least in part, on the discovery that metformin, a widely prescribed anti-diabetic drug, can affect the tumor microenvironment (e.g., directly, i.e., independent of its effects on cancer cells themselves or tumor metabolism). In embodiments described herein, metformin has been shown to reduce the amount of extracellular matrix, including collagen 1 and hyaluronan, in the fibro-inflammatory tumor microenvironment in a subject (e.g., a subject with a desmoplastic tumor).

The present invention relates to pharmaceutical compositions comprising {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid (FRI-1) in combination with an anti-diabetic drug selected from the group consisting of metformin, sitagliptin or exenatide. The present invention also relates to the use of the pharmaceutical compositions in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.

The invention relates to composite dietary fiber which is mainly prepared from 20-93 parts of dietary fiber, 10-30 parts of L-arabinose, 5-20 parts of isomaltulose, 1-5 parts of root of kudzu vine and 1-5 parts of folium mori in parts by weight. The composite dietary fiber has the beneficial effects that the composite dietary fiber is obvious in effect of controlling rise of postprandial blood sugar, improving sugar tolerance and other aspects; the composite dietary fiber, when being used, not only can be independently taken but also can be combined with other oral hypoglycemic drugs or insulin, and can take an excellent mutual promoting effect. The composite dietary fiber is simultaneously applicable to six groups: people of diabetes and instable postprandial blood sugar, people of cardiovascular and cerebrovascular diseases, people at risk of colitis, people of constipation, people of obesity, women, etc.

The invention provides a method for constructing a related intestinal canal-pancreatic islet regulation axis function evaluation model. The method includes: allowing a subject to take different oral hypoglycemic drugs or blank control in different stages, then performing intravenous-oral dual hyperglycemic clamp tests on the subject in each stage, drawing an area under the curve for a serum insulin value, a C-peptide value, a plasma glucagon value and an active glucagon-like polypeptide-1 (GLP-1) value acquired through the dual hyperglycemic clamp tests in each stage, and applying Metlab to perform 3D (three-dimensional surface fitting on the areas under the curve in one-to-one correspondence to obtain the related intestine-pancreas axis function evaluation model. By the method, two-phase insulin secretion patterns in intravenous-oral glucose stimulation states can be evaluated and compared accurately, besides, intestinal canal hormone effect and insulin-glucagon secretion can be related quantitatively, and accordingly an accurate intestine-pancreas axis effect model evaluation system is obtained.

The invention discloses a simple oral hypoglycemic traditional Chinese medicine of sweat potato leaf and process for preparation. Plant of sweat potato leaf is refluxed, extracted and concentrated through ethanol and ethanol extract is obtained. The ethanol extract after being absorbed through macroreticular absorbing resin is respectively eluted through distilled water, 10-20% ethanol and 40-60% ethanol, and the eluent liquid is concentrated and then is extracted through acetic ether. The extracting liquid is recycled and concentrated and extractum is obtained. The extractum is dried and the effective component of the sweat potato leaf--sweat potato leaf flavone is obtained. Tested by pharmacological experiment, sweat potato leaf flavone without toxic and side effects has the effect of reducing blood glucose and action time is lasting, thereby the invention can be used for curing type II diabetes and complication and provides a natural hypoglycemic medicament for non- insulin dependent diabetes mellitus (NIDDM).

The invention discloses a radix pseudostellariae homogeneous polysaccharide for promoting insulin secretion of islet cells and use thereof. The radix pseudostellariae homogeneous polysaccharide provided by the invention is acidic polysaccharide, has a molecular weight of 4.8*10<4> Da and specific rotation [alpha] of D<25>+174.5DEG (c 0.485, H2O); the molecular formula consists of three elements: C, H, O, and C, H and O are in a ratio of 1:2.1:1.4. The radix pseudostellariae homogeneous polysaccharide is composed of monosaccharide galacturonic acid, rhamnose, galactose and arabinose, galactose uronic acid is a main monosaccharide component of polysaccharide, alpha-1, 4- connected galacturonic acid constitutes a main chain of polysaccharide. Part of galacturonic acid C6-OH undergoes methyl esterification, the hydroxyl on C2 and C3 are partly acetylized, a small amount of rhamnose exists on the main chain, and 1, 5- connected arabinose composes a branched chain. The radix pseudostellariae homogeneous polysaccharide can promote insulin secretion of Ins-1 cells, and provides the basis for application in development of anti-diabetic drugs, health care products and other fields in the future.

The invention relates to application of an oral hypoglycemic peptide. The application is used for preparing a medicine or a medicine composition for treating or preventing diabetes complicated with cardiovascular diseases. The oral hypoglycemic peptide is polypeptide OHP2. The polypeptide can effectively improve myocardial hypertrophy and fibrosis damage caused by the diabetes, reduce the contentof related myocardial enzymes, adjust the lipid metabolism level and improve myocardial cell oxidative stress and mitochondrial damage, so that the effect of protecting the heart is achieved; and therefore, the polypeptide can be used as a candidate molecule for treating or preventing the diabetes complicated with the cardiovascular diseases (especially diabetic cardiomyopathy), and has a good application prospect.

The invention specifically relates to an anti-diabetic drug containing wild chrysanthemum flower extract, belonging to the technical field of anti-diabetic drugs. The wild chrysanthemum flower extract in the anti-diabetic drug contains sesquiterpenoids disclosed in the invention; the sesquiterpenoids can substantially inhibit accumulation of triglyceride and total fat in the differentiation process of 3T3-L1 preadipocytes, and the inhibitory effect is superior to the inhibitory effect of a positive control compound, i.e., berberine; and the sesquiterpenoids can also obviously activate liver X receptors alpha and beta (LXR alpha and LXR beta), wherein the activation effect of the sesquiterpenoids is better than the activation effect of a conventional LXR agonist tool molecule GW3965, and in particular, a compound 4 has obviously better activation effect compared with GW3965. Moreover, the sesquiterpenoids can adjust the mRNA expression of transcription factors SREBP-1c, PPAR gamma and CEBP delta of vital importance to metabolism of cholesterol. Thus, the anti-diabetic drug containing the wild chrysanthemum flower extract in the invention has good hpyerglycemic effect and presents good development prospects in treatment of diabetes.